Vesigen to Present New Preclinical Data on Ophthalmology Applications of Engineered ARMMs at 2024 ARVO Annual Meeting
CAMBRIDGE, Mass., May 1, 2024 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that the Company will be presenting two posters sharing new preclinical data from its engineered ARMMs platform at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The meeting will be held in Seattle, Washington from May 5-9.
Vesigen’s technology comprises engineered forms of a class of naturally existing vesicles to enable efficient functional delivery of complex intracellular payloads, while overcoming challenges observed with other modalities such as tissue specificity, toxicity, and re-dosability.
Vesigen will present preclinical data demonstrating successful biodistribution of its engineered ARMMs to non-human primate (NHP) photoreceptors and retinal pigment epithelium. The Company will also share new preclinical NHP data demonstrating functional delivery of genome editors to the retina and supporting therapeutic use of ARMMs in ocular diseases.
Details of the poster presentations are listed below. For more information about the ARVO Annual Meeting, including registration details, please visit https://www.arvo.org/annual-meeting/.
ARMMs as Non-Viral Vehicles for the Delivery of Genome Editors to Treat Stargardt Disease
- Poster Number: A0081
- Date: May 6 at 3:00pm EST
- Session: 245
- Location: Exhibit Hall
Biodistribution of ARMMs as Non-Viral Vehicles for Therapeutic Payloads by Sub-Retinal Administration in Minipigs and NHP
- Poster Number: B0291
- Date: May 8 at 2:15pm EST
- Session: 449
- Location: Exhibit Hall
About Vesigen Therapeutics
Vesigen Therapeutics is a biotechnology company developing a novel, non-viral delivery technology for gene editing, RNA, and protein-based therapeutics. Vesigen’s patented technology, ARMMs (ARRDC1 Mediated Microvesicles), can precisely deliver a wide range of payloads to a unique set of tissue and cell types. Vesigen has demonstrated highly efficient in vitro and in vivo functional delivery of a range of payloads across multiple cell types and is committed to developing transformative medicines that address current unmet medical needs. ARMMs were discovered and engineered into a drug delivery system at the Harvard T.H. Chan School of Public Health.
For additional information visit www.vesigen.com.
Investor and Media Contact:
Adam Bero, Ph.D.
Kendall Investor Relations
abero@kendallir.com
